ArticleAnnals of surgical oncology2025

Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy.

Kojiro Omiya et al.PubMed ↗Publisher ↗

No numbers read from the abstract.